Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07791615 Stapokibart Extranodal NK-T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791615 clinical trial report covering Stapokibart, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07796113 Adebrelimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07796113 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07791498 Teclistamab Waldenstrom's macroglobulinaemia refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791498 clinical trial report covering Teclistamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07795749 Paclitaxel Adenocarcinoma of large intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795749 clinical trial report covering Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
ChiCTR2600131184 Thymalfasin Node-positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600131184 clinical trial report covering Thymalfasin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07796126 Albumin-Bound Paclitaxel Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07796126 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07795814 EDG-15400 Heart failure with normal ejection fraction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795814 clinical trial report covering EDG-15400, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07794488 Recombinant Human Endostatin (Simcere) Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794488 clinical trial report covering Recombinant Human Endostatin (Simcere), Phase 2, endpoints, sponsor, geography, readout timing and development w
Read →
Latest Hotspot
8 min read
NCT07795424 Trastuzumab Hormone receptor positive HER2 positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795424 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07793942 Epinephrine Bitartrate Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793942 clinical trial report covering Epinephrine Bitartrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07770984 Ombitasvir/Paritaprevir/Ritonavir Hepatitis C Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07770984 clinical trial report covering Ombitasvir/Paritaprevir/Ritonavir, Phase 2/3, endpoints, sponsor, geography, readout timing and development whit
Read →
Latest Hotspot
8 min read
NCT07795177 Rezvilutamide Hormone-dependent prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795177 clinical trial report covering Rezvilutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
<
1
<<
379
380
381
382
383
>>
2260
>